Entry Strategy of the Indian Pharmaceutical Companies in Africa, CIS and the Middle East

Roshni Majumdar
{"title":"Entry Strategy of the Indian Pharmaceutical Companies in Africa, CIS and the Middle East","authors":"Roshni Majumdar","doi":"10.2139/ssrn.2162547","DOIUrl":null,"url":null,"abstract":"The social, economic and demographic context, in which the global pharmaceutical industry functions, is altering. The already developed economies, with escalation in healthcare expenses are looking to rein in healthcare disbursements. In developing economies as Africa, CIS & Middle-East the pharmaceutical industries are also undergoing a phase of dynamic change. The changes are brought about by revolutionary initiatives taken by the government of the constituent nations and the world around. Rising health consciousness, prevalence of diseases, and healthcare expenditure will help the MENA (Middle-East & North Africa) pharma market to grow at a CAGR of approx. 9.5% during 2011-2013. The pharma market in this region will continue to grow due to the high demand of drugs, even though there are multitudes of political issues in the region, which can potentially harm the industry. It is found that Saudi Arabia, South Africa, Africa, Algeria, & Egypt are the main defining markets in the region, and they will continue to dominate the market in future also. However, other countries, such as the UAE, Nigeria, CIS, and Israel have a lot of untapped potential, which can be utilized by the pharma companies. To capitalize on the opportunities in the Middle East & Africa pharma market, the multinational companies are looking to penetrate the market through individual or collaborative efforts. Joint ventures and other distribution agreements with the local companies will provide multinationals the advantage of having a better understanding of the market and its demands. Emerging economies as India & China certainly, propose a beam of optimism for the global pharmaceutical industry. The product development skills and scientific talent in India are being increasingly sought after by the pharmaceutical MNCs to confront the trials of growth and innovation. Indian pharmaceutical companies are also watching to move ahead in the value chain and alter the perception of India as a low-priced manufacture base to that of a unpretentious intellectual contributor. Various policies being introduced are related to the strengthening of the IPR protection laws, providing incentives, and tax exemptions to the foreign and domestic companies, and improving the marketing & distribution channels as well.","PeriodicalId":375570,"journal":{"name":"Diversification Strategy & Policy eJournal","volume":"36 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diversification Strategy & Policy eJournal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.2162547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The social, economic and demographic context, in which the global pharmaceutical industry functions, is altering. The already developed economies, with escalation in healthcare expenses are looking to rein in healthcare disbursements. In developing economies as Africa, CIS & Middle-East the pharmaceutical industries are also undergoing a phase of dynamic change. The changes are brought about by revolutionary initiatives taken by the government of the constituent nations and the world around. Rising health consciousness, prevalence of diseases, and healthcare expenditure will help the MENA (Middle-East & North Africa) pharma market to grow at a CAGR of approx. 9.5% during 2011-2013. The pharma market in this region will continue to grow due to the high demand of drugs, even though there are multitudes of political issues in the region, which can potentially harm the industry. It is found that Saudi Arabia, South Africa, Africa, Algeria, & Egypt are the main defining markets in the region, and they will continue to dominate the market in future also. However, other countries, such as the UAE, Nigeria, CIS, and Israel have a lot of untapped potential, which can be utilized by the pharma companies. To capitalize on the opportunities in the Middle East & Africa pharma market, the multinational companies are looking to penetrate the market through individual or collaborative efforts. Joint ventures and other distribution agreements with the local companies will provide multinationals the advantage of having a better understanding of the market and its demands. Emerging economies as India & China certainly, propose a beam of optimism for the global pharmaceutical industry. The product development skills and scientific talent in India are being increasingly sought after by the pharmaceutical MNCs to confront the trials of growth and innovation. Indian pharmaceutical companies are also watching to move ahead in the value chain and alter the perception of India as a low-priced manufacture base to that of a unpretentious intellectual contributor. Various policies being introduced are related to the strengthening of the IPR protection laws, providing incentives, and tax exemptions to the foreign and domestic companies, and improving the marketing & distribution channels as well.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度制药公司在非洲、独联体和中东的进入战略
全球制药业所处的社会、经济和人口背景正在发生变化。随着医疗费用的上升,已经发达的经济体正在寻求控制医疗支出。在非洲、独联体和中东等发展中经济体,制药业也正在经历一个动态变化的阶段。这些变化是由各组成国政府和世界各国采取的革命行动带来的。不断提高的健康意识、疾病的流行和医疗保健支出将有助于MENA(中东和北非)制药市场以大约的复合年增长率增长。2011-2013年9.5%。由于药品需求旺盛,该地区的医药市场将继续增长,尽管该地区存在大量可能损害该行业的政治问题。研究发现,沙特阿拉伯、南非、非洲、阿尔及利亚和埃及是该地区的主要决定性市场,未来它们也将继续主导市场。然而,其他国家,如阿联酋、尼日利亚、独联体和以色列,有很多未开发的潜力,这些潜力可以被制药公司利用。为了利用中东和非洲制药市场的机会,跨国公司正在寻求通过个人或合作的努力渗透市场。与当地公司的合资企业和其他分销协议将为跨国公司提供更好地了解市场及其需求的优势。印度和中国等新兴经济体无疑为全球制药行业带来了乐观的曙光。印度的产品开发技能和科学人才越来越受到制药跨国公司的追捧,以应对增长和创新的考验。印度制药公司也在关注在价值链上的前进,并将印度作为一个低价制造基地的印象转变为一个谦逊的智力贡献者。正在出台的各种政策涉及加强知识产权保护法律,为国内外公司提供奖励和免税,以及改善营销和分销渠道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Diversification as a Strategic Choice for Yangguang Takeaway Restaurant When Does Limited Commitment Matter in a Production Economy? Cross-Border Acquisitions and the Asymmetric Effect of Power Distance Value Difference on Long-Term Post-Acquisition Performance Collaboration between Competitors' NPD Teams: In Search of Effective Modes of Management Control Diversifying Risk Parity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1